Lane Generational LLC grew its position in ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) by 53.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 242,045 shares of the company's stock after acquiring an additional 84,350 shares during the quarter. ClearPoint Neuro makes up approximately 3.2% of Lane Generational LLC's holdings, making the stock its 14th largest position. Lane Generational LLC owned 0.87% of ClearPoint Neuro worth $2,878,000 at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in CLPT. Bank of America Corp DE lifted its holdings in shares of ClearPoint Neuro by 211.9% in the 4th quarter. Bank of America Corp DE now owns 42,307 shares of the company's stock worth $651,000 after purchasing an additional 28,742 shares during the last quarter. Man Group plc bought a new stake in shares of ClearPoint Neuro in the 4th quarter worth approximately $1,107,000. Tower Research Capital LLC TRC bought a new stake in shares of ClearPoint Neuro in the 4th quarter worth approximately $93,000. Millennium Management LLC lifted its holdings in shares of ClearPoint Neuro by 5.0% in the 4th quarter. Millennium Management LLC now owns 289,150 shares of the company's stock worth $4,447,000 after purchasing an additional 13,866 shares during the last quarter. Finally, Barclays PLC lifted its holdings in shares of ClearPoint Neuro by 1,070.9% in the 4th quarter. Barclays PLC now owns 66,436 shares of the company's stock worth $1,022,000 after purchasing an additional 60,762 shares during the last quarter. 30.08% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on the company. Stifel Nicolaus increased their price objective on ClearPoint Neuro from $19.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. Wall Street Zen downgraded ClearPoint Neuro from a "hold" rating to a "sell" rating in a research note on Saturday, July 12th.
Read Our Latest Stock Analysis on ClearPoint Neuro
Insider Activity
In other ClearPoint Neuro news, Director Timothy T. Richards sold 10,000 shares of the company's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $13.28, for a total value of $132,800.00. Following the transaction, the director owned 77,381 shares of the company's stock, valued at approximately $1,027,619.68. This represents a 11.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Joseph Burnett sold 21,247 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $13.29, for a total value of $282,372.63. Following the completion of the transaction, the chief executive officer directly owned 243,522 shares in the company, valued at $3,236,407.38. This represents a 8.02% decrease in their position. The disclosure for this sale can be found here. Company insiders own 6.97% of the company's stock.
ClearPoint Neuro Stock Down 0.4%
ClearPoint Neuro stock traded down $0.05 during mid-day trading on Friday, hitting $11.23. 303,633 shares of the company's stock traded hands, compared to its average volume of 561,961. The firm has a 50 day moving average price of $11.90 and a 200 day moving average price of $13.61. The company has a market cap of $314.33 million, a PE ratio of -14.78 and a beta of 0.92. ClearPoint Neuro, Inc. has a one year low of $6.25 and a one year high of $19.22.
ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.07). ClearPoint Neuro had a negative net margin of 64.51% and a negative return on equity of 78.09%. The business had revenue of $8.49 million for the quarter, compared to the consensus estimate of $8.21 million. On average, analysts expect that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current fiscal year.
About ClearPoint Neuro
(
Free Report)
ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.
Featured Stories
Before you consider ClearPoint Neuro, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ClearPoint Neuro wasn't on the list.
While ClearPoint Neuro currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
